The stock of Pliant Therapeutics Inc (PLRX) has gone up by 1.95% for the week, with a -7.81% drop in the past month and a -2.60% drop in the past quarter. The volatility ratio for the week is 7.23%, and the volatility levels for the past 30 days are 6.50% for PLRX. The simple moving average for the last 20 days is -6.54% for PLRX’s stock, with a simple moving average of -2.07% for the last 200 days.
Is It Worth Investing in Pliant Therapeutics Inc (NASDAQ: PLRX) Right Now?
PLRX has 36-month beta value of 1.06. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PLRX is 53.76M, and currently, short sellers hold a 13.42% ratio of that float. The average trading volume of PLRX on November 21, 2024 was 407.97K shares.
PLRX) stock’s latest price update
The stock price of Pliant Therapeutics Inc (NASDAQ: PLRX) has jumped by 2.91 compared to previous close of 12.73. Despite this, the company has seen a gain of 1.95% in its stock price over the last five trading days. globenewswire.com reported 2024-11-18 that INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of clinical data at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) being held in San Diego, California.
Analysts’ Opinion of PLRX
Many brokerage firms have already submitted their reports for PLRX stocks, with Leerink Partners repeating the rating for PLRX by listing it as a “Outperform.” The predicted price for PLRX in the upcoming period, according to Leerink Partners is $33 based on the research report published on September 09, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see PLRX reach a price target of $41. The rating they have provided for PLRX stocks is “Overweight” according to the report published on December 08th, 2023.
Canaccord Genuity gave a rating of “Buy” to PLRX, setting the target price at $48 in the report published on May 18th of the previous year.
PLRX Trading at 0.03% from the 50-Day Moving Average
After a stumble in the market that brought PLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.23% of loss for the given period.
Volatility was left at 6.50%, however, over the last 30 days, the volatility rate increased by 7.23%, as shares sank -6.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.77% upper at present.
During the last 5 trading sessions, PLRX fell by -0.70%, which changed the moving average for the period of 200-days by -20.10% in comparison to the 20-day moving average, which settled at $14.00. In addition, Pliant Therapeutics Inc saw -27.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PLRX starting from Lefebvre Eric, who sale 12,319 shares at the price of $11.56 back on Jul 10 ’24. After this action, Lefebvre Eric now owns 213,052 shares of Pliant Therapeutics Inc, valued at $142,408 using the latest closing price.
Hull Hans, the Chief Business Officer of Pliant Therapeutics Inc, sale 9,900 shares at $11.56 during a trade that took place back on Jul 10 ’24, which means that Hull Hans is holding 227,494 shares at $114,444 based on the most recent closing price.
Stock Fundamentals for PLRX
Current profitability levels for the company are sitting at:
- -45.88 for the present operating margin
- 0.67 for the gross margin
The net margin for Pliant Therapeutics Inc stands at -41.67. The total capital return value is set at -0.55. Equity return is now at value -47.52, with -40.90 for asset returns.
Based on Pliant Therapeutics Inc (PLRX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.41. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -88.44.
Currently, EBITDA for the company is -158.23 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 159.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.26.
Conclusion
To put it simply, Pliant Therapeutics Inc (PLRX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
